Combined Treatment with Erlotinib and a Transforming Growth Factor-β Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non–Small-Cell Lung Cancer Cells
Keywords: ارلوتینیب; Epidermal growth factor receptor tyrosine kinase inhibitors resistance; Erlotinib; Motility; Transforming growth factor beta signaling; Non–small-cell lung cancer